Adding glofitamab to chemotherapy for aggressive lymphomas
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests adding a new immunotherapy drug called glofitamab to standard chemotherapy for aggressive lymphomas. The goal is to see if the combination is more effective at shrinking or eliminating the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and have Burkitt lymphoma, double hit lymphoma, or relapsed/refractory lymphoma.
- If you have Burkitt lymphoma or double hit lymphoma, you must have at least one high-risk feature (advanced stage, high LDH, or a large tumor).
- You can have had no prior treatment, or only one cycle of chemo or a short pre-phase, within the last 21 days.
- Your kidneys, liver, and blood counts must be within acceptable ranges (some flexibility if abnormal due to lymphoma).
- You must not have active infections, certain autoimmune diseases, or a history of a rare immune condition called HLH.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called glofitamab (given with standard chemotherapy) for people with untreated mantle cell lymphoma. It aims to see if adding this drug helps control the cancer better than chemotherapy alone.
This study tests an extra treatment called glofitamab (given as an infusion) after your first therapy has worked well, to help keep the lymphoma from coming back. It is for people with high-risk large B-cell lymphoma, and aims to improve long-term remission.
This trial tests a new drug called glofitamab combined with standard chemoimmunotherapy (called R-CHOP) for people with HIV-related large B-cell lymphoma that has not been treated before. The goal is to see if adding this drug improves outcomes and is safe.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.
This study tests a new combination of drugs for people with aggressive B-cell lymphoma that has not gotten better or has come back. The goal is to see if the combination helps control the cancer.
Hear when a new Recurrent Burkitt Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.